MX2021012146A - Formulacion de tableta vaginal. - Google Patents

Formulacion de tableta vaginal.

Info

Publication number
MX2021012146A
MX2021012146A MX2021012146A MX2021012146A MX2021012146A MX 2021012146 A MX2021012146 A MX 2021012146A MX 2021012146 A MX2021012146 A MX 2021012146A MX 2021012146 A MX2021012146 A MX 2021012146A MX 2021012146 A MX2021012146 A MX 2021012146A
Authority
MX
Mexico
Prior art keywords
tablet formulation
vaginal tablet
vaginal
glucono
lactone
Prior art date
Application number
MX2021012146A
Other languages
English (en)
Inventor
Olov Sterner
Ulf Ellervik
Helena Strevens
Sophie Manner
Nils - Olof LINDBERG
Annette Säfholm
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of MX2021012146A publication Critical patent/MX2021012146A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende glucono d-lactona, que es adecuada para uso en el tratamiento de infecciones microbianas vaginales.
MX2021012146A 2019-04-05 2020-04-03 Formulacion de tableta vaginal. MX2021012146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05
PCT/EP2020/059582 WO2020201515A1 (en) 2019-04-05 2020-04-03 Vaginal tablet formulation

Publications (1)

Publication Number Publication Date
MX2021012146A true MX2021012146A (es) 2021-12-10

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012146A MX2021012146A (es) 2019-04-05 2020-04-03 Formulacion de tableta vaginal.

Country Status (24)

Country Link
US (1) US20220193031A1 (es)
EP (1) EP3976000B1 (es)
JP (1) JP2022537478A (es)
KR (1) KR20210148195A (es)
CN (1) CN113660928B (es)
AR (1) AR118580A1 (es)
AU (1) AU2020252268A1 (es)
BR (1) BR112021019999A2 (es)
CA (1) CA3134086A1 (es)
CL (1) CL2021002430A1 (es)
CO (1) CO2021014253A2 (es)
EA (1) EA202192716A1 (es)
ES (1) ES2961736T3 (es)
HU (1) HUE062772T2 (es)
IL (1) IL286942A (es)
MA (1) MA56011A (es)
MX (1) MX2021012146A (es)
PE (1) PE20220381A1 (es)
PL (1) PL3976000T3 (es)
SG (1) SG11202110236QA (es)
TW (1) TW202103693A (es)
UA (1) UA127823C2 (es)
WO (1) WO2020201515A1 (es)
ZA (1) ZA202106877B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69802260T2 (de) * 1998-04-30 2002-07-04 Vesely Renata Maria Cavaliere Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2017174731A1 (en) * 2016-04-06 2017-10-12 Gedea Biotech Ab Glucono delta-lactone for treatment of vaginal fungal infections
MX2020003660A (es) 2017-10-06 2020-08-03 Gedea Biotech Ab Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.

Also Published As

Publication number Publication date
SG11202110236QA (en) 2021-10-28
WO2020201515A1 (en) 2020-10-08
JP2022537478A (ja) 2022-08-26
CN113660928A (zh) 2021-11-16
PL3976000T3 (pl) 2023-12-04
ZA202106877B (en) 2023-03-29
AR118580A1 (es) 2021-10-20
CO2021014253A2 (es) 2021-11-19
EA202192716A1 (ru) 2022-01-17
IL286942A (en) 2021-12-01
HUE062772T2 (hu) 2023-12-28
BR112021019999A2 (pt) 2021-12-07
CA3134086A1 (en) 2020-10-08
EP3976000A1 (en) 2022-04-06
TW202103693A (zh) 2021-02-01
MA56011A (fr) 2022-04-06
CL2021002430A1 (es) 2022-07-01
EP3976000C0 (en) 2023-08-02
AU2020252268A1 (en) 2021-10-21
ES2961736T3 (es) 2024-03-13
US20220193031A1 (en) 2022-06-23
UA127823C2 (uk) 2024-01-10
PE20220381A1 (es) 2022-03-18
EP3976000B1 (en) 2023-08-02
KR20210148195A (ko) 2021-12-07
CN113660928B (zh) 2024-04-05

Similar Documents

Publication Publication Date Title
MX2023002507A (es) Inhibidores de cd73.
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
PH12019502646A1 (en) Pyrazole magl inhibitors
GEP20227443B (en) Magl inhibitors
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
PH12019502548A1 (en) Pyrazole magl inhibitors
PH12021551268A1 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
NZ788133A (en) Cd73 inhibitors
PH12018500358A1 (en) Compounds for use in an antibacterial applications
CR20210507A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020005344A (es) Compuestos de pirazolopiridinona.
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
PH12018502131A1 (en) Glucono delta-lactone for treatment of vaginal fungal infections
MX2021012146A (es) Formulacion de tableta vaginal.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
PL425328A1 (pl) Zastosowanie α,β-dihydroksantohumolu